Sibel H. Blau
Experienced in Chronic Myelogenous Leukemia (CML)

Dr. Sibel H. Blau

Hematology Oncology | Oncology
Puyallup, WA 
Accepting New Patients
Offers Telehealth
Experienced in Chronic Myelogenous Leukemia (CML)
Puyallup, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sibel Blau is an Oncologist in Puyallup, Washington. Dr. Blau is rated as an Experienced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Triple-Negative Breast Cancer, and Pleuropulmonary Blastoma. Dr. Blau is currently accepting new patients.

Her clinical research consists of co-authoring 32 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Cerrahpasa Faculty Of Medicine, Istanbul University
Residency
Case Western Reserve University, Cleveland, OH
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in WA
Board Certifications
Medical Oncology
Fellowships
Case Western Reserve University, Cleveland, OH
Fred Hutchinson Cancer Research Center, Seattle, WA
Hospital Affiliations
St Joseph Medical Center
St Anthony Hospital
St Clare Hospital
St Francis Community Hospital
Multicare Good Samaritan Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Moda Health
  • EPO
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 17 Less Insurance Carriers -

Locations

Northwest Medical Specialties - Puyallup
Puyallup, WA 98373

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 2
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Drug
Study Drug: ARX788
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Drug
Study Drugs: LEE011, Letrozole, BYL719
Study Phase: Phase 1/Phase 2
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
A Phase II, Multicenter, Randomized, Open-label Study to Evaluate the Safety and Efficacy of 400 mg of Ribociclib in Combination With Non-steroidal Aromatase Inhibitors for the Treatment of Pre- and Postmenopausal Women With Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole or Anastrozole, Goserelin
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting
Enrollment Status: Terminated
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: Trilaciclib, Sacituzumab Govitecan-hziy
Study Phase: Phase 2
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drugs: Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Study Phase: Phase 2
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
EPIK-B4: A Phase II, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR During Treatment With Alpelisib (BYL719) in Combination With Fulvestrant in Participants With HR+, HER2-, Advanced Breast Cancer With a PIK3CA Mutation Following Progression on/After Endocrine-based Therapy
Enrollment Status: Terminated
Publish Date: October 09, 2024
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Metformin, Dapagliflozin
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants With Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drugs: Lerociclib, Letrozole, Fulvestrant
Study Phase: Phase 2
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole, Goserelin, Leuprolide
Study Phase: Phase 3
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: September 21, 2022
Intervention Type: Drug, Dietary supplement, Biological
Study Drugs: Telaglenastat, Carboplatin Chemotherapy, Pemetrexed Chemotherapy, Pembrolizumab Immunotherapy, Dexamethasone
Study Phase: Phase 2
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Enrollment Status: Terminated
Publish Date: March 23, 2022
Intervention Type: Drug
Study Drugs: Trilaciclib, Gemcitabine, Carboplatin
Study Phase: Phase 2
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer
Enrollment Status: Terminated
Publish Date: September 30, 2021
Intervention Type: Other
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
Enrollment Status: Terminated
Publish Date: May 28, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 16 Less Clinical Trials

32 Total Publications

Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care.
Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care.
Journal: American journal of clinical oncology
Published: December 10, 2025
Similar Doctors
Elite in Chronic Myelogenous Leukemia (CML)
Dr. Vivian G. Oehler
Oncology | Hematology Oncology
Elite in Chronic Myelogenous Leukemia (CML)
Dr. Vivian G. Oehler
Oncology | Hematology Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (24.6 miles away)
206-598-4333
Languages Spoken:
English, German, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Vivian Oehler is an Oncologist and a Hematologist Oncology provider in Seattle, Washington. Dr. Oehler is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Leukemia, Philadelphia-Negative Chronic Myeloid Leukemia, and Bone Marrow Aspiration. Dr. Oehler is currently accepting new patients.

Elite in Chronic Myelogenous Leukemia (CML)
Dr. Jerald P. Radich
Oncology
Elite in Chronic Myelogenous Leukemia (CML)
Dr. Jerald P. Radich
Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (23.1 miles away)
206-288-1000
Languages Spoken:
English, Filipino, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jerald Radich is an Oncologist in Seattle, Washington. Dr. Radich is rated as a Distinguished provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). Dr. Radich is currently accepting new patients.

Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Jennifer N. Slim
Hematology Oncology | Hematology | Oncology
Distinguished in Chronic Myelogenous Leukemia (CML)
Dr. Jennifer N. Slim
Hematology Oncology | Hematology | Oncology

Multicare Health System

317 Mlk Jr Way, Multicare Social Work Serv, 
Tacoma, WA 
 (6.4 miles away)
253-403-1126
Languages Spoken:
English, Malayalam, Spanish, Ukrainian, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Jennifer Slim is a Hematologist Oncology specialist and a Hematologist in Tacoma, Washington. Dr. Slim is rated as an Advanced provider by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). Her top areas of expertise are Familial Colorectal Cancer, Philadelphia-Negative Chronic Myeloid Leukemia, Chronic Myelogenous Leukemia (CML), and Thrombocytopenia. Dr. Slim is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blau's expertise for a condition
ConditionClose
View All 44 Advanced Conditions
View All 128 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile